Treating the president with Regeneron’s experimental antibody therapy creates a “very tough situation” for the company as the therapy has not received approval for widespread use, the company’s CEO said.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,